First communication on the efficacy of combined 177Lutetium-PSMA with immunotherapy outside prostate cancer

Prostate-specific membrane antigen (PSMA)-targeted radioligand therapy is a validated treatment option for patients with advanced prostate cancer. Although PSMA expression is not limited to prostate tissue, little is known about its relevance to other types of cancer. Here, we present a case report...

Full description

Bibliographic Details

Published in:	Journal for ImmunoTherapy of Cancer
Main Authors:	John Prior, Solange Peters, Krisztian Homicsko, Sarah Boughdad, Niklaus Schaefer, Antonia Digklia, Clarisse Dromain, Mounir Trimech, Ana Dolcan
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2022-10-01
Online Access:	https://jitc.bmj.com/content/10/10/e005383.full